

Electronic Certificate

Version: 1 . 0

Document Number: DK-AM2-2500022

Document Name: DK AM2 E-mail Praktisk Håndtering Instruktionsvideo Apr 25 LU DRA

Country: Denmark

Product: AM2M

Type: Material

Sub Type: Mailing

Classification:

Material Intent: Promotional

Description: DK AM2 E-mail Praktisk Håndtering Instruktionsvideo Apr 25 LU DRA

Target Audience: HCP Nurses

Method of Dissemination: E-Mailing

Certification Statement

We certify that the final electronic form of this material is in accordance with the regulations set forth by the health authority for the country of this document, and is a fair and truthful presentation of the facts about the product.

Role	Signature
Arex Advisor - Compliance Approval (promotion@otsuka-europe.com)	Meaning: As the Compliance, I approve this document for use. Date: 02-Sep-2025 11:59:59 GMT+0000

Subject: Praktisk håndtering instruktionsvideo

{{customRichText:Required}}



Her kan du se en instruktionsvideo, der viser, hvordan du praktisk håndterer Abilify Maintena® 960 mg. Klik på billedet for at se videoen (åbner i et nyt vindue).



Herunder kan du se, hvordan overgangen fra Abilify Maintena® 400 mg til Abilify Maintena® 960 mg skal håndteres.



Du kan også skifte patienter direkte fra oralt aripiprazol

Hvis patienten ikke behandles med aripiprazol, så skal tolerabilitet overfor aripiprazol fastslås, før behandling med Abilify Maintena® påbegyndes.¹

Se afsnit 4.2 i produktresumé for Abilify Maintena® 960 mg for yderligere information om dosering og administrering.¹

*Tidligst 26 dage efter foregående injektion.¹

Abilify Maintena® 960 mg er indiceret til vedligeholdelsesbehandling af skizofreni hos voksne patienter stabiliseret med aripiprazol.¹

Abilify Maintena® 400 mg er indiceret til vedligeholdelsesbehandling af skizofreni hos voksne patienter stabiliseret med oralt aripiprazol.¹

{{customRichText:Required}}

{{userName}}

{{userEmailAddress}}

{{UserPhone}}

Ref.

1) Abilify Maintena® produktresumé

Abilify Maintena® (aripiprazol) pligtttekst

Klik her



Otsuka Pharma Scandinavia AB
Sveavägen 151
113 46 Stockholm, Sweden
+46 545 286 60, www.otsuka.dk

Your personal data will be processed in accordance with the Otsuka HCP Privacy Notice, which is available [here](#). If you would like to withdraw your consent, you can unsubscribe to receiving emails related to this Therapy Area at any time and without reason by clicking on the unsubscribe link below or by emailing privacy@otsuka-europe.com.

Unsubscribe

Please send adverse events and/or product quality complaints to: opsab.vigilance@otsuka.se and medical information enquiries in English to: medical.information@otsuka-europe.com

DK-AM2-2500022 v 1.0. Date of preparation: 2025-04-01
